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The apparent beneficial effect of para-aminobenzoic acid (as sodium para-
aminobenzoate) in patients with certain forms of lupus erythematosus has been
described in preliminary reports (1, 2). These studies have continued and treat-
ment has now been extended to a total of 18 patients with various clinical forms
of lupus erythematosus.
The rationale for administering large doses of sodium para-aminobenzoate
(NaPAB) to patients with lupus erythematosus has been given previously (1)
and will, therefore, be referred to only briefly herein. Lupus erythematosus
is a disease of unknown etiology and treatment is of necessity on an empiric basis.
It is well known, however, that exposure to ultraviolet light may induce a relapse
or cause an exacerbation of the disease (3). Sensitivity to sunlight has also been
encountered in individuals receiving sulfanilamide or related compounds (4).
With these points in mind, and the knowledge that para-aminobenzoic acid and
sulfonamides are metabolite antagonists (5, 6, 7), it was reasoned that para-
aminobenzoic acid might produce a beneficial effect in lupus erythematosus (1).
Since large doses of PABA had been administered to patients with rickettsial
diseases (8, 9, 10) and leukemia (11) without serious toxic effects, it was judged
safe to test this hypothesis in patients with lupus erythematosus. This study
was undertaken, therefore, and it is the purpose of this communication to present
the results obtained to date.
For administration to the patients, crystalline para-aminobenzoic acid (PABA)
of high purity' was converted to a 10 per cent solution of sodium para-amino-
benzoate (NaPAB) in the manner previously noted (11). This was taken orally
in 20 cc. to 40 cc. doses (2.0 to 4.0 grams NaPAB) every two or three hours, day
and night, when the patient was in the hospital. Patients taking the drug at
home were instructed to increase the dose and the intervals for their night time
medication. Other modifications of the dosage schedule are indicated in the
individual case histories. The liquid form of NaPAB was usually given in a
small amount of fruit juice or ginger ale. Tablets (0.5 gm. each)2 of NaPAB
were also found to be a convenient form of medication, especially for patients
who continued to work during the period of therapy. Several patients found it
desirable to alternate from one form of NaPAB to the other. With the exception
of a few instances in which PABA ointment or lotion was applied locally for
* From the Departments of Internal Medicine and Dermatology and Syphilology, Uni-
versity Hospital, Ann Arbor, Michigan.
Read before the Ninth Annual Meeting of the Society for Investigative Dermatology,
Chicago, Illinois, June 20, 1948.
1 The para-aminobeuzoic acid used in this study was generously contributed by Merck
and Co., Rahway, N. J.
2 Tablets of Sodium PABA were kindly supplied by Wyeth and Co., Philadelphia, Pa.
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protective absorption of ultraviolet rays (12), no other treatment was given to
these patients during the present study.
Brief accounts of the clinical and laboratory findings, and of the courses of
patients receiving NaPAB therapy follow. For purposes of evaluation and dis-
cussion, the cases have been divided arbitrarily into four groups on the basis of
criteria indicated by Ormsby and Montgomery (3): (1) fixed or discoid lupus
erythematosus; (2) the chronic disseminated variety in which there are wide-
spread discoid lesions or lesions of a disseminate type without evidence of systemic
involvement; (3) subacute disseminated; and (4) acute disseminated lupus ery-
thematosus.
GROUP 1. DISCOID LUPUS ERYTHEMATOSUS
Case 1. C. B., a 42 year old white male cement finisher was admitted to the University
Hospital on February 4, 1947. The patient had been well until 14 months previously when
he first noted the onset of progressive loss of hair from the scalp. About four months prior
to admission, red, scaly lesions appeared on the temporal regions. New lesions gradually
appeared on the nose, cheeks, and chin. Mild pruritus was present at times in these lesions.
Examination revealed many areas of alopecia in the scalp. These varied in size, were
atrophic, and were surrounded by an erythematous scaling border. Over the temples,
cheeks, nose and chin were about a dozen erythematous plaques which ranged from 1.0 to
2.5 centimeters in size. The borders were raised and active, and there was central atrophy.
The lesions were covered by a thick, adherent scale which exhibited "carpet-tacking" on
removal.
Laboratory studies on admission revealed 4,700 white blood cells per cubic millimeter
with 47 per cent polymorphonuclear leukocytes. The hemoglobin was 15.5 grams per cent.
Urinalysis was negative and the urea clearance test normal. Ultraviolent sensitivity
tests revealed the patient to require 1.5 times the normal dosage to obtain erythema.
Course and Treatment: The patient received 4 grams NaPAB every two hours for eight
days, and 3 grams every two hours for six days. At the end of this time there was no ap-
parent change in the lesions and treatment was discontinued, and the patient discharged.
Comment: This patient failed to obtain benefit on two weeks of NaPA.B
therapy. In view of later experience, however, it is possible that treatment was
not continued long enough to obtain a response.
Case 2. F. A., a 40 year old white housewife, was admitted to the University Hospital
on June 16, 1947. Thirteen years previously she had had an erytheniatous eruption over
the cheeks and nose which cleared completely following intramuscular gold and bismuth
therapy. In July 1944, she developed a small lesion over the bridge of the nose. This
gradually increased in size despite treatment with gold and bismuth. Promin was also
tried without benefit.
Examination revealed circumscribed, erythematous lesions over the nose, forehead and
right cheek. There was peripheral activity and central atrophy. The lesions were covered
by a thick, adherent, white scale.
Laboratory studies revealed the blood and urine examinations to be normal. An ultra-
violet skin sensitivity test was normal. A biopsy specimen revealed a histologic picture
compatible with the diagnosis of discoid lupus erythematosus.
Course and Treatment: On June 20, the patient was given 36 grams NaPAB daily.
This was reduced to 24 grams daily on June 25, when she was discharged to continue therapy
at home. By August 18, the patient's lesions had shown little, if any, improvement and she
complained of general malaise, weakness and somnolence. The white cells numbered
2,300 with 46 per cent neutrophiles. NaPAB was discontinued until September 30, when it
TREATMENT OF LIJPUS ERYTHEMATOSU5 31
was resumed for one month. Except for a decrease in the degree of crythema, there was no
significant change in the lesions and the administration of NaPAB was stopped.
Comment: NaPAB therapy in courses of 2 months and 1 month, respectively,
failed to benefit appreciably the lesions of this patient.
Case 3. N. 0., a 72 year old white housewife, was first seen in 1940, with an crythem-
atous, elevated lesion on the tip of the nose. The lesion presented telangicctasia and
patulous follicles. The diagnosis of discoid lupus crythematosus was made, and treatment
consisted of intravenous gold injections, quinine orally, and a quinine and bismuth paste-
locally. The lesion cleared in 1941, but new lesions appeared on the forehead and neck.
These subsequently cleared, however. In 1943, and again in 1944, she developed a gen-
eralized erythcmatons, papular eruption following the administration of a sulfonamide.
During the summer of 1947, facial lesions re-appeared and similar areas were observed on
the arms. Intravenous gold therapy was again followed by improvement. In November
1947, however, she was treated with one of the sulfonamide compounds for an attack of
pleurisy. The lesion on the nose flared, and she developed an erythematous, papular,
pruritic eruption on the face, neck and arms which was similar to the previous sulfonamide
eruptions. She was admittod to the University Hospital on December 11, 1947.
Examination revealed generalized senile artophy of the skin. Over the cheeks and nose
were several small, circumscribed erythematous lesions which were covered by a thick
adherent scale. Atrophy was present centrally. There was a bright red, papular eruption
over the arms and neck.
Laboratory examinations of the blood and urine were negative. A biopsy specimen
taken from the right cheek was histologically compatible with the diagnosis of lupus cry-
thematosus. Another specimen taken from the left wrist, however, did not have the
changes needed for the pathologic diagnosis of this condition.
Course and Treatment: The patient received 24 grams NaPAB daily for 11 days. At the
end of this time, the sulfonamide rash had cleared entirely, and the lupus arythematosus
lesions had cleared remarkably. The patient was discharged without further treatment.
Comment: Evaluation is not possible in this case because of the concomitant
sulfonamide rash. Nevertheless, the patient's response while receiving NaPAB
was in the direction of rapid improvement.
Case 4. M. P., a 32 year old white housewife, was admitted to the University Hospital
on February 4, 194S. Three years before, she had developed two small scaly lesions on the
bridge of the nose. Several small areas of alopecia appeared shortly afterwards. In
September 1945, the patient received two injections of gold intravenously. A marked
exfoliative reaction followed which included loss of the nails, and was accompanied by
severe burning, lacrimation and redness of the eyes. As the dermatitis cleared, the patient
noted that the lupus erythomatosus lesions had disappeared, but her eyes failed to improve.
She has since been seen frequently in the Ophthalmology Out-patien Service for treat-
ment of a chronic kerato-conjunctivitis. About four months before admission the patient
again noted a small erythematous, scaly lesion on the bridge of the nose. Other lesions
then appeared on the tip of the nose and on both lips.
Examination of the scalp revealed four 1.0 to 2.5 centimeters broad lesions exhibiting
telangieetasia and atrophy. There were three sharply defined erythematous, scaling
lesions on the nose (Figure la), and papulo-squamous lesions of the mucous membranes of
the lips.
Laboratory examination revealed the urine to be normal. The white blood cell count
was 5,500 per cubic millimeter with 43 per cent polymorphonuclear leukocytes.
Course and Treatment: The patient was given 2 grams of NaPAB every 2 hours, or 24
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grams daily. Within a week, definite improvement was noted in the skin and mucous
membrane lesions. There was also diminution of the injection of the eonjunctivae and
decrease in photophobia and lacrimation. The patient was discharged on February 15,
and was instructed to continue on NaPAB, 24 grams daily. On February 17, she developed
abdominal, back and leg cramps and fever to 104°F. She discontinued the NaPAB and felt
better within a few hours. The next day she resumed the medication but after two doses,
the same symptoms recurred. NaPAB was not taken again until February 19, when the
patient was readinitted to the hospital. At that time, she was given NaPAB under ob-
servation, and after a total of 14 grams was taken, the patient complained of abdominal and
leg cramps, and her temperature rose to 103.4°F. She soon recovered, and on February 23,
a test dose of 2 grams NaPAB was administered. One hour later, the patient felt "prickly
all over," and at the end of the second hour, an erythematous, multiform rash had appeared
over the entire body. There was, however, no fever at this time. The patient was placed
on Neo-antergen and the rash and symptoms subsided rapidly. NaPAB was, of course, not
A B
FIG. 1. PHoToeaAPHs OF PATIENT 4
A. At the beginning of therapy.
B. Improvement in lesions ever bridge of nose and on lower lip is evident, 22 days later.
given again. Figure lb depicts the status of this patient's lesions at the termination of
therapy.
Comment: A gratifying therapeutic response was being observed in this
patient when NaPAB treatment had to be discontinued because of the develop-
ment of drug fever and dermatitis medicamentosa.
Cuse 5. P. H., a 43 year old white male printer, was admitted to the University Hospital
on December 29, 1947. He gave a history of progressive weight less, drowsiness, and daily
fever of 102—104°F of 6 months duration. Fifteen years previously he had reddened, in-
durated lesions over both cheeks which were treated with x-ray irradiation. The lesions
subsided, the cheeks became sunken, and the skin became taut and was easilyirritated.
In the fall of 1947, similar lesions appeared about the angles of the iasv and on the chin and
forehead. These lesions were red and scaly but were asymptomatie.
Physical examination revealed the patient's temperature to be 103°F. The skin of his
cheeks was atrophic and shiny. There were circular, erythemateus lesions about 2.5
centimeters in diameter on the chin, jaw and forehead. Central atrophy and sealing were
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present in these lesions. Numerous scarred, pigmented atrophic areas were present on
the lateral aspects of the face. Examination of the eyes showed small ulcers of the lids
keratitis and symblepharon which the ophthalmologist believed might be due tolupua
erythematosus. The remainder of the physical examination was negative.
Laboratory studies were extensive and only the more pertinent results will be given.
Repeated urine analyses were negative. The white blood cells numbered 12,000 per cubic
millimeter on admission, and the hemoglobin was 14 grams per cent. The urinary creatine
excretion was 0.522 grams in 24 hours. The blood non-protein nitrogen and urea clearance
determinations were within normal range. Agglutination tests for brucellosis, typhoid and
paratyphoid were negative. Roentgen examination of the chest revealed hilar and para-
tracheal lymph node enlargement without parenehymal abnormality. The tuberculin test
was po8itive at 24 hours in 1:10,000 dilution. An ultraviolet skin sensitivity test gave a
normal reaction in one-half the normal time. Microscopic examination of biopsy speci-
mens taken from the lesions on the chin and forehead revealed changes compatible with
lupus erythematosus.
Course and Treatment: The patient received NaPAB, 24 grams daily, for one week
beginning on January 3. His eye symptoms improved, but as he remained highly febrile, it
was decided to discontinue NAPAB therapy until additional studies were completed.
On February 4, NaPAB administration was resumed on the 24 gram per day schedule. The
patient was discharged on February 13 and instructed to continue this program. NaPAB
was taken until February 20, when it was discontinued. The patient's general condition
had become progressively worse, and he remained febrile and continued to lose weight.
NaPAB was resumed from March 9 to 15, when the patient was readmitted to the Uni-
versity Hospital. At this time there was no evidence of active lesions of the face. X-ray
studies showed bilateral hilar and right paratracheal lymphadenopathy with coarse granu-
larity of both lung fields. There were marked changes from the fiuidings of the previous
examination on January 13. Sputum collections were made for culture, and then strepto-
mycin therapy was begun. Within a few days there was marked improvement, and the
temperature fell to near normal levels. Meanwhile, pre-streptomycin sputum cultures
yielded acid-fast bacilli. On April 9, three small right supraclavicular nodes were removed
and examined histologically. Fibrocaseous tuberculosis replacing lymph nodes was noted
and miliary tubercles were present. As of June 12, the patient was afebrile, had experi-
enced a 30 pound weight gain, and streptomycin therapy was being continued. It is of
interest that in the past month there has been a gradual reappearance of erythematous
scaly lesions on his face which appear to be a recurrence of lupus erythematosus.
Comment: This patient is believed to have chronic discoid lupus erythematosus
which responded to NaPAB therapy, and miliary tuberculosis which is responding
to streptomycin.
Case 6. L. R., a 31 year old negro housewife, noticed scaling and loss of hair at the
anterior hairline in August 1945. She was first seen at the University Hospital in March
1946, at which time the diagnosis of discoid lupus erythematosus was made. The patient
received intravnous gold sodium thiosulfate at weekly intervals from March 30, 1946 to
August 9, 1946. Bismuth subsalicylate in oil was administered intramuscularly at weekly
intervals from January 22, 1947 to April 17, 1947. There was no further therapy and the
condition gradually progressed. Pruritus was intense when the patient was admitted to
the University Hospital on March 22, 1948.
Examination revealed scattered areas of alopecia of the scalp. The borders of these
areas were erythematous and there was atrophy at the centers. Numerous plugged,
dilated hair follicles were present in these lesions.
Laboratory studies revealed normal blood cell values, urinalysis was negative and the
urea clearance test was normal. Microscopic examination of a biopsy specimen from the
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scalp revealed moderate atrophy of the epidermis with marked cornification which filled
the openings of the hair follicles. Areas of necrosis and of hyaline change were present in
the dermis. Lymphocytic inflammatory foci were noted. There was atrophy of the sweat
glands and disappearance of sebaceous glands.
Course and Treatment: On March 25, the patient was placed on NaPAB therapy, 24
grams daily. After 10 days there was diminution in the amount of pruritus, and the lesions
appeared to be less active. She was discharged to continue medication at home. She
returned on April 27 because of exacerbation of an old gastric condition. She had dis-
continued the NaPAB four days previously. Examination revealed additional improve-
ment of the scalp lesions and most of the erythema had subsided. The patient no longer
experienced itching. Because of the gastro-intestinal disturbance, however, no further
therapy with NaPAB was attempted.
Comment: Some objective improvement was noted in this patient's lesions
following NaPAB treatment. Subjectively, the areas of involvement becaxre
non-pruri tic.
GROUP 2. CHRONIC DISSEMINATED LUPUS ERYTHEMATOSUS
Case 7. G. K., a 40 year old white draftsman, first noticed a few red spots on his right
cheek and temple in December 1946. These gradually extended peripherally and became
confluent. In January, a few similar lesions appeared, on the left side of his face. All
lesions progressed gradually until his admission to the University Hospital on February 12,
1947. During the preceding nine months, he had noticed some ease of fatigue and oc-
casional episodes of stiffness and aching in the ankles, knees, shoulders and fingers.
Examination revealed several fairly well circumscribed erythematous, edematous lesions
over the lower temples and upper cheeks bilaterally. The largest was 1.5 centimeters in
diameter. There was some confluence. The follicles in the lesions were patulous. There
was no scaling.
Laboratory findings included normal blood and urine values. The urea clearance test
was normal. An ultraviolet skin sensitivity test gave a normal reaction in one-third the
normal time. Microscopic examination of a biopsy specimen revealed morphologic changes
characteristic of lupus erythematosus (Figure 2a).
Course and Treatment: On February 14, he was started on 24 grams NaPAB daily.
Fading of all lesions was practically complete by March 6. Another biopsy specimen taken
at this time was found to have much less lymphocytic infiltration than the pre-treatment
specimen (Figure 2h). An ultraviolet skin sensitivity test showed a normal response in
one-half the normal exposure time. Treatment was discontinued and the patient was
discharged from the hospital on March 6.
About five days before his return for check-up examination on March 19, he noticed the
reappearance of red lesions which then gradually increased in size. A biopsy specimen
was taken and showed lymphocytic infiltration comparable to that observed in the first
specimen, as well as the histologic features of lupus erythematosus (Figure 2c.). The white
blood cell count was now 2,450 per cubic millimeter. The patient was again given 24 grams
NaPAB daily, and his lesions faded considerably within a week. By April 19, only a faint
residual erythema remained. The white cell count returned to normal. Biopsy was again
performed and microscopic examination revealed only a minimal lymphocytic infiltrate
(Figure 2d). NaPAB therapy was discontinued on May 10, and the patient's face remained
clear for about 2 weeks after which he noted the beginning of recurrence of lesions.
Comment: This patient's lesions were twice cleared with NaPAB and re-
appeared each time after cessation of therapy.
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Fin. 2. PIIOTOMICEOGEAPHS OF Bros SPECIMENS TAKEN FEOM PATIENT 7
A. Specimen at beginning of treatment.
B. Specimen at conclusion of first course of NaPAB.
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C. Specimen taken from lesion after relapse, and just before second course of therapy.
D. Specimen taken after re-institution of therapy for one month.
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Case 8. E. P., a 50 year old white plant manager, was admitted to the University Hos.
pital on April 7, 1947. He gave a history of extensive scaling erythematous lesions over the
face and ears for 10 years. He had received bismuth injections periodically for six years
without change. On two occasions he received intravenous injections of gold, and each was
followed by generalized erythema. Numerous forms of local therapy were used with little
effect. The patient had observed that his lesions were made worse by exposure to sunlight.
Examination revealed numerous discrete, erythcmatous lesions of varied size over the
ears, face and neck. Adherent white scales covered these lesions (Figure 3a). The edges
of the lesions were elevated, and atrophy was present centrally. The oars were red, ede-
matous and extremely tender.
Laboratory studies showed normal blood and urine findings. A biopsy specimen re-
vealed a picture histologically compatible with lupus crythematosus. An ultraviolet skin
sensitivity test gave a normal reaction in one-third the normal time.
A B
Fm. 3. PHOTOGRAPHs OF PATIENT S
A. At the beginning of NaPAB administration.
B. Same patient 5 weeks later.
Course and Treatment: The patient was begun on NaPAB therapy, 24 grams daily, on
April 10, and was discharged on April 13 to continue treatment at home. By April 21, his
lesions were much improved. The erythcma had faded and his cars were not swollen and
tender. Treatment was continued until early in May, when he experienced a reaction to thc
drug characterized by flushing and fever to 103°F. The reaction subsided after a few hours,
but recurred after each of two subsequent doses. Unfortunately, there was no opportunity
to test this patient's drug sensitivity under observation.
Comment: There was definite improvement from NaPAB therapy (Figure
3b), but treatment was discontinued because of the development of drug fever.
Case 9. J. A. C., a 35 year old white sheet metal worker, was first seen at the Derma-
tology Clinic on September 29, 1947. For 5 years, he had had an eruption which began on
his right chock and gradually spread to involve the "butterfly" area of the face, and later
the anterior portion of the neck. The eruption usually became worse in the summer and
tended to clear in winter. However, it did not clear much during the winter of 1946, and had
spread more than usual the following summer.
Examination revealed an crythematous, papular eruption involving the cheeks, bridge of
the nose, forehead and anterior neck. There were both discrete and confluent lesions.
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B
FIG. 4. PHOTOMICEOGEAPHS OF BIOPSY SPECIMENS TAKEN FEOM PATIENT 9
A. Before NaPAB therapy.
B. After 1 month of treatment.
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Central atrophy was present in some of the larger ones. Telangiectasia was noted, but
there was no scale, and no gross fnllieular plugging.
Laboratory examinations revealed normal urine and blood values. A biopsy specimen
taken from the neck revealed histologic changes characteristic of lupus erythematosus
(Figure 4a).
Course and Treatment: On October 1, the patient began taking 24 grams NaPAB daily,
and he was also given PABA lotion for application to exposed areas. By October 29, there
remained only a few small erythematnus areas on the neck and atrophic scars at the sites of
previous lesions. The changes seen in the pretreatment biopsy specimen were present to a
lesser extent in a specimen taken at this time (Figure 4b). On November 24, the patient
was clinically clear of lesions and NaPAB therapy was discontinued.
The patient returned for examination on May 7, 1948. He stated that he remained clear
of lesions until early January 1948, at which time a few lesions appeared. He took 4 grams
of NaPAB daily for about one week and the lesions cleared again. On April 28, he became
aware of new lesions en his face and neck. These had gradually spread and were accom-
panied by sensations of burning and itching. Examination en May 7, confirmed the pres-
ence of several lesions on the face and neck and NaPAB therapy was re-instituted. By
May 28, there was no pruritus or burning in the lesions and they had faded appreciably.
Much of the edema present in them at the beginning of therapy was gone. At the present
writing, the patient is continuing on 24 grams daily of NaPAB.
Comment: An excellent response to NaPAB therapy was obtained in this
case. Lesions recurred, however, a few weeks after cessation of therapy. The
patient treated himself with small doses of NaPAB, and it is said his lesions
cleared. Another relapse is now being treated under observation and the lesions
are again regressing.
Case 10. R. L., a 45 year old white physician, first noted lesions on the dorsal aspects of
his thumbs in August 1940. These cleared spontaneously that fall, but recurred to a
greater extent the following year. He was seen by Dr. Udo J. Wile in 1941, and the diag-
nosis of lupus erythematesus was made. The eruption cleared entirely following a course of
gold therapy, but recurred in 1942. Gold and bismuth injections did not help at this time,
and lesions also appeared on the face. The patient noted that exposure to sunlight caused
a flare-up of his lesions, and on one occasion he developed fever to 103°F, and malaise
following such an exposure.
Course and Treatment: The patient has not been under immediate observation but has
kindly kept us informed of his progress. In July 1947, he began taking about 12 grams
NaPAB daily. After 5 days, he decreased the dosage to 6 grams daily because of a gastritis
caused by the drug. The patient states that improvement was noticeable within 3 days
and that his face cleared completely in 3 weeks. Imprnvement of lesions en the hands
occurred at a slower rate as they were more extensively involved. The patient has con-
tinued to take NaPAB for over 9 months at the present writing, and the improvement has
been maintained. He still takes 2 grams NaPAB with each meal and only occasionally
misses a dose. In addition, he has used PABA lotion as a light proteetant, but takes no
other precautions as to light exposure.
Comment: This patient has had an excellent response with a relatively small
total daily dosage of NaPAB.
Case 11. J. G., a 27 year old white male student, developed red, swollen and scaling
lesions en both cheeks after considerable exposure to the sun in August 1947. He was
treated with PABA lotion at the Student Health Service, and the lesions cleared tempo-
rarily, only te recur again after re-exposure to the sun. He was referred to the University
Hospital for further study and treatment in November 1947.
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Examination at that time revealed diffuse, slightly raised erythematous lesions over both
cheeks. Telangiectasia and slight sealing were present. The hair follicles in the involved
areas were patulous.
Laboratory studies revealed normal blood and urine findings. An ultraviolet skin
sensitivity test gave a normal reaction only after one and two-thirds the normal exposure
time. A biopsy specimen revealed histologic changes compatible with the diagnosis of
lupus erythematosus.
Course and Treatment: On November 20, the patient began NaPAB therapy, 2 grams
every 2 hours from 7:00 A.M. to 11:00 P.M., or 18 grams daily. In two weeks time there was
marked fading of the lesions and by January 9, they were no longer grossly evident. Treat-
ment was continued and another biopsy specimen was taken on February 9 from a point
adjacent to the pre-treatment biopsy site. The pathologist noted that lymphoeytie in-
filtration about the vessels and accessory skin structures was much less in this than in the
previous specimen. The findings, however, were compatible with lupus erythematosus,
particularly when compared to the pre -treatment specimen.
Comment: This patient's lesions have remained in remission during the 7
months that he has received 18 grams NaPAB daily. The same program is con-
tinuing at the present writing.
Cuss 112. J. F. C., a 34 year old white public accountant, was first seen at the University
Hospital on January 8, 1948. One year previously, a red, scaling lesion had appeared on his
left cheek. This spread rapidly to involve the other cheek as well. The patient noted some
ease of fatique and he became quite nervous and irritable. Treatment consisted of in-
traniuseular bismuth, Bistrimate, quinine and x-ray irradiation with no effect. He also
received a two week course of a sulfonamide compound, following which there occurred
swelling of the bands and face.
Examination revealed large, confluent, erythematous, scaly, slightly elevated plaques on
each cheek. Similar, smaller lesions were present on the nose, left eyelid, the ears, the back
of the neck, and on the right arm. There was also some telangieetasia.
Laboratory findings included normal blood and urine values. An ultraviolet skin scm-
sitivity test gave a normal reaction in one-third the normal time. Microscopic examination
of a biopsy specimen taken from a lesion on the right arm revealed changes compatible with
lupus erythematosus.
Course and Treatment: On January 9, the patient began NaPAB therapy, 24 grams daily.
He discontinued medication at the end of 3 weeks because he began to experience trouble-
some pruritus in the lesions shortly after taking each dose. The patient returned on
February 6, and he was given a test dose of 2 grams NaPAB. Within a few minutes the
patient complained of itching, but as this was transient and not associated with systemic
manifestations, treatment was resumed. He was also given 3 per cent PABA cream to
apply locally before undertaking prolonged exposure to the sun. By March 5, the lesions
were paler and showed evidence of central scarring. He also noted marked improvement
in his sense of well-being, and he no longer experienced itching after taking his medication.
He continued to take 18—24 grams of NaPAB daily. Examination on June 9, and com-
parison with pre-treatment photographs revealed definite improvement in the lesions which
were also less extensive in area. Scarring had progressed, the lesions were flat and there
was less scale. Brownish pigmentation had appeared about the periphery of most of the
lesions.
Comment: This patient had very gradual but definite improvement during
5 months of almost continuous NaPAB therapy.
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GROUP 3. SUBACUTE DISSEMINATED LUPUS ERYTHEMATOSUS
Case 13. E. W., a 35 year old white male veteran, first noticed a large erythematous
plaque on the back of the scalp in September 1945. The hair was soon lost from this area.
This was followed by the appearance of multiple lesions over the scalp, face, ears, neck,
back and extremities. When first seen at the University Hospital in May 1946, he com-
plained of severe pruritus.
Examination revealed four large circular, erythematous areas of alopecia in the scalp.
The centers of these lesions were atrophic. Erythematous plaques with atrophic centers
and adherent scales were found on the face, behind the ears and on the lower extremities.
Over the back and on both arms were numerous punctuate, erythematous papules covered
with silvery scale.
Course and Treatment: The patient was referred to the Veteran's Administration for
treatment, but failed to report to them. He was next seen on October 29, at which time a
marked progression of lesions was noted. He had become quite nervous, tired easily and
had lost 30 pounds. He also complained of severe itching and burning. He was admitted
to the hospital where he was kept at strict bed rest. Five per cent PABA cream was applied
locally. Urinalysis revealed 2 red cells per high power field. Other laboratory tests were
normal at this time. On November 7, he was much improved; his urine was normal, and he
was discharged from the hospital.
Shortly after discharge, he suffered an acute exacerbation of all lesions and was read-
mitted to the hospital on December 20. His condition became steadily worse. Red blood
cells were again found in the urine. His white blood cell count dropped to 4,600 with a
predominance of lymphocytes. He became very weak and exhausted, and suffered from
pain and burning in his lesions. Three blood transfusions were given with little change.
On January 20, 1947, he responded sluggishly.
The following day, NaPAB therapy was started, the patient receiving 2 grams every 2
hours. This was increased to 48 grams daily on January 23, because of low blood levels.
By January 27, he was feeling much better, and there was much less erythema in the lesions.
The next day the dose was decreased to 36 grams daily because of anorexia. He was photo-
graphed at this time (Figure 5a). An ultraviolet skin sensitivity test on January 31, re-
vealed a normal reaction in one-fourth normal time. Improvement continued, and scar-
ring became apparent in the lesions. Treatment was discontinued on February 19, and he
was discharged on February 23. He returned on April 29, feeling well. The skin had con-
tinued to improve, and the blood and urine examinations were normal. A few days before
his next visit on June 6, he noticed the onset of numerous, generalized, small, psoriasiform
lesions. No specific diagnosis could be made from examination of a biopsy specimen from
one of these areas. His face and neck, however, showed evidence of additional improve-
ment since the previous examination (Figure Sb). A few active lesions were noted and were
believed to represent recurrence of lupus erythematosus. Urinalysis was negative. The
leukocyte count was 4,600. An ultraviolet skin sensitivity test gave a normal reaction in
two-thirds the normal time. NaPAB therapy was resumed at home. Medication was dis-
continued after 2 weeks, however, because the patient experienced pruritus a few minutes
after each dose. He did not return for re-examination until December 5, at which time he
was generally much improved. There appeared to be some recurrence of activity of lesions
on the left ear. In view of the history of prnritus following medication, a test dose of
NaPAB was given on December 8, and failed to elicit such a response.
Comment: A very Satisfactory result was attained with NaPAB therapy in
this ease.
Case 14. H. K., a 44 year old white housewife, was first seen in the University Hospital
on September 25, 1947. In 1943, a red lesion was noted on the forehead. This gradually
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spread over the nose and cheeks, and subsequently, similar lesions appeared on the neck,
chest and arms. Exposure to sunlight caused reddening of the lesions and intense pruritus.
X-ray treatments were followed by an exacerbation. Gold and bismuth injections had no
effect. Multiple arthralgias occurred during the summer of 1947, and were quite incapaci-
tating.
Examinations revealed numerous, fairly well circumscribed, erythcmatous plaques and
papules in the above mentioned areas. There was central atrophy, telangiectasia, adherent
scales and follicular plugging in many of the lesions. Although there was pain and tender-
ness in many of the joints, there was no limitation of motion.
A B
FIG. 5. PHOTOGRAPHs OF PATIENT 13
A. After 7 days of therapy with NaPAB.
B. After 4 months of intermittent NaPAB treatment.
Laboratory studies: Urinalysis revealed a one plus albumin. Blood studies were nor-
mal. Microscopic examination of a biopsy specimen revealed a picture characteristic of
lupus erythematosus.
Course and Treatment: On September 29, she was started on 24 grams NaPAB daily.
A 5 per cent PABA ointment was given for local application. By October 6, the lesions bad
faded considerably. Her arthralgias were much relieved, and subjectively, she felt much
better. Both objective and subjcctivc improvement continued until the end of October.
The medication then caused nausea, however, and was discontinued on November 1. Mi-
croscopic examination of a biopsy specimen rcvcalcd the changes seen previously but much
less lymphocytic infiltrate. Six weeks later her skin showed further improvement. There
was much evidence of scarring, but erytherna and telangicctasia remained within the scars.
About 10 days before, she had endured a prolongcd exposure to the cold, and this was fol-
lowed by generalized arthralgias. Another course of therapy with NaPAB, 18 grams daily,
was started on December 15, and continued until April 22, 1948. The arthralgias again
improved. All of the lesions became scarred and depressed, but tclangicctasia persisted in
r ___
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the sear tissue. However, the patient developed a urinary tract iofection and NaPAB was
discontinued until this could be cleared. Meanwhile arthralgias increased progressively
and became incapacitating. Treatment with NaPAB was resumed on May 21, and by June
4, some relief of pain was already noticeab]e.
Comment: This patient experienced relief from arthralgias each time NaPAB
therapy was instituted and exacerbations of pain after cessation of therapy.
Concomitant improvement of cutaneous lesions also occurred with each course of
therapy.
Case 15. M. H., a 21 year old white waitress, was first seen in the University Hospital
in December 1946. Five years before she had developed erythematous, scaling, slightly
pruritic lesions on the sides of the nose and over the cheeks. These persisted and were
aggravated by sunlight. More recently, new lesions developed on the arms, loss of hair
set in, and ease of fatigue was noticed.
Examination revealed a diffuse flush on the sides of the nose and over the chocks. There
was telangiectasia and follicular plugging. The scalp hair was thin.
Laboratory studies: Blood and urine examinations were normal. Microscopic examina-
tion of a biopsy specimen revealed a picture compatible with lupus erythematosus.
Course and Treatment: Intramuscular bismuth was given over a period of two months
with some improvement. She was not seen again until October 16, 1947, at which time the
eruption was much wider in distribution, more erythematous and more infiltrated. The
hair loss had continued. Exposure to sunlight caused a tightness in her chest which made
her "gasp for breath." A biopsy at this time was similar to the previous one. On October
16, she was started on 24 grams NaPAB daily. In 2 weeks, her skin was much improved,
and at the end of two months, only a faint residual erythema remained. She had gained
weight and no longer experienced ease of fatigue. Microscopic examination of a biopsy
specimen revealed much less perivascular round cell infiltrate than seen previously. Treat-
ment was discontinued on December 18. She returned on March 2, 1948, and stated that 3
weeks after discontinuing treatment, she noticed reddening at the angles of the nose. This
gradually spread to involve both cheeks. Her ease of fatigue gradually returned, and on
several occasions she had stiffness and pain in the metacarpal-phalangeal joints of both
hands. Examination revealed an eruption similar to the previous one (Figure 6a). There
was also some loss of hair from the eyebrows. NaPAB was resumed, and by March 22, the
skin was almost entirely clear (Figure 6b), although the ease of fatigue persisted. The
patient continued to take NaPAB at home until April 22. In a letter dated May 22, the
patient states that her face had remained clear and that she felt more energetic than she
had in a long time.
Comment: This patient's lesions regressed both times NaPAB therapy was
undertaken.
Case 16. 5. 5., a 4 year old white female, developed red patches on the cheeks at the
ago of 2. These gradually spread over the bridge of the nose and became elevated. In
July 1946, the eruption spread to the arms and legs. She was admitted to the University
Hospital on July 11, 1946.
Examination revealed an erythematous, diffuse, maculopapular eruption over the cheeks,
bridge of the nose, forehead and chin. The arms and legs were involved with a similar, more
discrete process. There were several erythematous patches on the oral mucosa. Cener-
alized lymphadenopathy was present at this time.
Laboratory studies: Blood and urine examinations were normal.
Course and Treatment: She was treated with Fowler's solution but soon developed
edema of the eyelids. She was then given Lugol's solution for two weeks with no change
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and discharged from the hospital. She was next seen on March 2, 1948. During the in-
terim, the lesions on the extremities had cleared leaving residual pigmentation. The face
had also cleared temporarily, but the eruption recurred 3 months prior to this visit. Ex-
amination revealed erythematous, slightly sealing patches on both cheeks, over the bridge
of the nose, under the chin and behind both ears. There was some telangieetasia present.
The hard palate was also involved. She was started on NaPAB, I gram every 3 hours, on
March 3. The patient continued on this schedule at home for 10 days without apparent ill
effect. Indeed, the cutaneous lesions were fading rapidly \vhen the child developed an-
orexia and nausea on March 14. NaPAI3 was discontinued and the child was examined by
a pediatrician. This examiner noted the liver edge to descend 1 finger breadth below the
eostal margin and the eluid had slight fever. There were no other abnormal findings.
A 13
Fm. 5. PnoTooaApHs OF' PAT[ENT 15
A After relapse and at beginning of second course of NaPAB therapy.
13. After 20 days of second course of treatment.
On the following morning, the patient suddenly had high fever and convulsive movements
and was hospitalized. The attending physicians found no localizing signs and the blood
and urine findings were normal. Despite all forms of emergency treatment the child be-
came comatose and died in a few hours. Permission for autopsy examination was obtained
and the gross findings revealed a moderately enlarged, pale yellow liver. Otherwise the
findings were not remarkable. Preliminary studies of the microscopic sections of the liver
reveal changes of an acute toxic hepatitis.
Comment: This patient was receiving NaPAB therapy with apparent good
results when an acute toxic state occurred. It seems probable that death was
due to toxic hepatitis possibly resulting from idiosyncrasy to NaPAB.
Case 17. B. P., a 19 year old white unmarried female office clerk, was admitted to the
University Hospital on May 12, 1948. The patient gave a history of frost-bite involving
a a—I
•
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the fingers of bath hands during the winter of 1946—47. In the autumn of 1947, she first
noted pallor of the fingers on exposure tn cold. In January 1948, there appeared a red,
blotchy eruption on the anterior aspect of the thighs. Under local treatment these cleared
in about 2 weeks. In early February the patient developed an erythematous, maeular
eruption over the forearms, cheeks and neck. There was no associated pruritus. An cry-
thematous change also occurred in fhe fingertips. In March, the involvement on the face
tended to localize in a butterfly distribution over the nose and cheeks. Weakness, ease of
fatigue and swelling of the right knee were noticed. Soon there was also puffiness of fhe
hands and wrists.
Examination at the time of admission revealed an erythematous, macular eruption on
the eyelids, cheeks, bridge of the nose and chin. A similar eruption with slight scaling
appeared on the chest, back and arms. The fingertips were erythematous. The hands and
wrists were markedly edematous, hut there was minimal edema at the ankles. The tip of
the spleen was just palpable on deep inspiration. The remainder of the physical examina-
tion was negative.
Laboratory studies revealed normal blood and urine values. A biopsy specimen taken
from the left cheek showed hyperkeratosis with keratohyalin plugs in the skin orifices,
and lymphocytic infiltrations about the accessory skin structures.
Course and Treatment: The patient was given NaPAB, 2 grams every 2 hours, beginning
on May 14, 1948. The medication was well tolerated and considerable clearing occurred
within a few days in both the eruption and in the amount of edema. The patient felt
stronger and there was improvement in the sense of well-being. She was discharged on-
May 26, to continue therapy at home. Medication was changed to an equal mixture of 10
per cent solutions of sodium para-aminobenzoatc and potassium para-aminobenzoate. In
tins manner the amount of sodium intake was decreased in the hope of accelerating the
loss of edema fluid. The patient returned for re-examination on June 4. She had continued
to improve and felt fine. The face and other skin areas appeared practically normal. There
was no residual erythcma and only slight thickening. The fingertip changes were still
present, and there was still a slight aniount of edema of the right hand. Treatment is
being continued.
Comment: Improvement in the cutaneous manifestations and in the amount
of edema has occurred during NaPAB and KPAB therapy.
GROUP 4 ACUTE DISSEMINATED LUPUS EEYTHEMATOSUS
Case 18. P. 5., an 18 year old white female, '.vas admitted to the hospital on February
25, 1948. Tn May 1947, she developed two crythcniatous, scaling lesions about 5 centi-
meters in diameter on the cheeks and a similar lesion over the bridge of the nose. These
cleared in several weeks after local therapy. However, about a month later, a diffuse,
crythematous, scaling eruption appeared over the cheeks and nose. Generalized aching
and ease of fatigue occurred. Her appetite was poor and there was moderate weight loss.
11cr temperature ranged between 100 and 103 degrees. Courses of penicillin and liver ex-
tract had no affect.
Examination revealed a well-developed, fairly well nourished girl who appeared chron-
ically ill. There was a diffuse, scaling, erythematous eruption over the nose and checks.
The scales ware somewhat adherent, and there was follicular plugging. There were also
many crythematous, papulosquamous lesions over the forehead, chin, neck and scalp.
Flare hemorrhages ware scan beneath the fingernails. The temperature was 102.2° on ad-
mission.
Laboratory studies: White blood call count was 5,500 par cubic nullimeter. Urinalysis
revealed two plus albuminuria. The urea clearance test was normal. An ultraviolet skin
sensitivity test yielded a normal reaction.
Course and Treatment: On February 28, she w-as started on 16 grams NaPAB daily.
This was increased to 24 grams on March 1. On March 4, her temperature rose to 103°,
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nausea and vomiting occurred, and medication was discontinued the following day. The
temperature remained high, and periods of mental confusion occurred. The involved skin
areas became more crythematous, and more splinter hemorrhages were noted on the finger
tips. On March 8, 500 cc. whole blood was given, and the patient seemed improvcd for
several hours. However, diarrhea soon set in, and the temperature rose to 104 degrees,
where it remained until the patient expired on March 12, 1948.
Permission was obtained for a rcstricted autopsy and the pathologic diagnosis of dis-
seminated lupus crythcmatosus was madc.
Comment: It is difficult to evaluate the effect of NaPAB therapy in this
case, although, of course, the fatal outcome makes it an ultimate failure in this
instance. On the other hand, the patient was acutely ill and the drug was tol-
crated only for one week when it was discontinued because of nausea and vomiting
and mounting fever.
DISCUSSION
It appears evident from the foregoing case histories that most of these patients
had an apparent beneficial effect during treatment with sodium para-aminoben-
zoate. To be sure, lupus erythematosus is notably unpredictable in its clinical
course. The causal relationship between therapy and response in these cases,
however, is too consistent to be attributed to chance remission. Especially
does this seem to be evident from the results in patients 7, 9, 14, and 15. The
lesions of each of these individuals improved greatly during NaPAB treatment
and reappeared some time after the administration of the drug was discontinued.
In each instance, a second course of therapy again resulted in regression of the
lesions. Furthermore, it should be noted that remissions were maintained as
long as the compound was administered in adequate dosage.
Two of the 6 patients with chronic discoid lupus erythematosus (Group 1)
failed to improve on NaPAB. One of these, however, was treated for only 2
weeks and this may have been too short a time to obtain an effect. The patients
in this group were treated for relatively short intervals, the longest continuous
period of therapy being 2 months. It is of interest that one of these patients
(Case 6) was at first believed to have acute disseminated lupus erythematosus.
Treatment with NaPAB caused regression of his cutaneous lesions, but failed to
affect his acute systemic manifestations which were later shown to be due to
miliary tuberculosis.
All 6 patients in Group 2, that is, those with chronic disseminated lupus cry-
thematosus, underwent improvement while receiving NaPAB. Two patients
have been on practically continuous treatment for 7 and 9 months, respectively,
and their lesions have remained in remission throughout.
Four of the 5 patients with subacute disseminated lupus erythematosus (Group
3) also experienced a beneficial response to treatment. The other patient, the
4 year old child, apparently died of toxic hepatitis which probably represents
idiosyncrasy to the drug. The dosage was only S grams daily which is much less
than has been readily tolerated by other children (10). It should also be noted
that this patient's cutaneous lesions were definitely improving during therapy.
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Experience in the treatment of acute disseminated lupus erythematosus (Group
4) was limited during this study to one case. NaPAB was administered to this
patient for one week when it had to be discontinued because of nausea and vomit-
ing. This patient died a few days later. NaPAB failed to alter the course of
this patient's illness in the limited period of its administration. Further evalua-
tion of its effects in this form of lupus erythematosus, however, must await trial
in additional cases.
In general, when a response to therapy was observed, it was characterized by
objective improvement in the cutaneous manifestations and increased tolerance
to sunlight. The skin lesions showed gradual fading of erythema and diminution
of the infiltration and edema. Many of the lesions disappeared completely.
On the other hand, atrophic, scarred and telangiectatic areas were unaffected as
was to be expected. Pre-treatment biopsy specimens were taken from 14 of
these patients, while post-treatment specimens have so far been removed for
examination from 4 cases. The most evident alteration in the pathologic picture
was a diminution in the degree of perivascular round cell infiltration. These
post-treatment biopsy specimens, however, retained sufficient changes in the
histologic architecture to suggest the diagnosis of lupus erythematosus.
Subjectively, the patients noted marked diminution to disappearance of sensa-
tions of itching and/or burning in the involved skin areas. Several noted an
improvement in their sense of well-being, with loss of mental clouding and apathy.
One patient experienced marked relief from troublesome arthralgias.
Ultraviolet skin sensitivity tests were done on 9 of the patients. Five of these
gave normal reactions in less than normal exposure time and were, therefore,
hypersensitive to ultraviolet light. All 5 of these subjects had a favorable re-
sponse to NaPAB therapy. Two patients had normal sensitivity and 2 were
resistant requiring prolonged exposure to obtain a normal response. One im-
proved and one failed to improve despite what appears to have been adequate
therapy. The others (Cases 1 and 18) also did not improve but treatment was
limited.
Untoward reactions of varied importance were encountered. The instance of
toxic hepatitis has already been mentioned, and of course, is of grave import.
In the light of present knowledge of the pharmacologic effects of para-amino-
benzoic acid, it is believed to have been a manifestation of drug idiosyncrasy.
On the other hand, the need for close observation of patients receiving NaPAB
therapy is further emphasized.
Drug fever was encountered in two patients and associated dermatitis medica-
mentosa in one of these. These reactions readily subsided on cessation of therapy.
It is of interest that both of these subjects had previously experienced serious
reactions after only 1 or 2 injections of gold compounds.
Nausea, sometimes accompanied by vomiting, occurred in some of the patients.
Omission of treatment for a few doses, or more, usually allowed sufficient recovery
and therapy could be resumed. Switching back and forth between liquid and
tablet forms of medication, and frequent changes in the type of vehicle used
(fruit juice, ginger ale, etc.) also aided in controlling these symptoms.
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Pruritus was noted a few minutes after a dose of the medicine by 2 of the
patients. This gradually subsided in one, and did not recur in the other follow-
ing a test dose given several weeks after treatment had been discontinued.
Edema may appear at times in patients receiving the sodium salt of para-
aminobenzoic acid. The potassium salt can be prepared readily and has been
used in a few of these patients as well as in patients with other entities (13).
Potassium para-aminobenzoate has been well tolerated and edematous patients
have lost fluid as well as obtaining the same therapeutic result expected from the
sodium salt.
Blood and urine examinations were done repeatedly in all but the patient not
under immediate observation. Although leukopenia was frequently encoun-
tered, it was not possible to attribute this to the drug because the entity itself is
characterized by a lowering of the white cell count. Furthermore, the leukocytes
often increased in number while therapy was continued. Nevertheless, the
possibility remains that agranulocytosis may rarely result from the administra-
tion of para-aminobenzoic acid and periodic blood examinations are desirable.
As previously described (1, 11) glycosuria occurs throughout the period of
treatment when a patient receives 18 or more grams of NaPAB per day. It was
possible to test the urine repeatedly in 16 of these 18 cases, and all 16 had one
plus to three plus glycosuria during therapy. This appears to be on a renal
basis. Only a few grams of glucose are lost daily and this is of little consequence
in patients who maintain a normal dietary intake. On the other hand, it should
be kept in mind that patients with prolonged periods of anorexia may undergo
an hypoglycemic attack.
It would be sheer speculation to attempt to explain the mode of action of
para-aminobenzoic acid in lupus erythematosus. The photo-chemical theory of
sunburn (12), however, might give a clue as to the manner in which the cutaneous
changes are brought about. On the other hand, there is highly suggestive evi-
dence that PABA acts in rickettsial infections by increasing the metabolism of
the parasitized cells (14). These and other possibilities need to be explored alone
and in relation to the unknown fundamental pathogenesis of lupus erythematosus
and related conditions.
A great deal of investigation obviously remains to be done. Para-amino-
benzoic acid is not a cure for lupus erythematosus. It is believed, however, that
the results presented herein warrant additional studies with the compound and
its derivatives.
SUMMARY
1. Para-aminobenzoic acid (as sodium or potassium para-aminobenzoate) was
administered to 18 patients with various clinical forms of lupus erythematosus.
2. Objective and subjective improvement occurred in most of the patients
receiving adequate treatment. (Only one case of acute disseminated lupus
erythematosus was included in this study and had a fatal outcome.)
3. Biopsy specimens revealed a marked diminution in the degree of round cell
infiltration following therapy.
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4. Relapses usually occurred after cessation of therapy.
5. Generally, the compound was well tolerated, but instances of nausea,vomit-
ing, pruritus, drug rash and drug fever were encountered.
6. One patient died of a toxic hepatitis, probably due to drug idiosyncrasy.
7. All patient receiving 18 or more grams daily of NaPAB had a concomitant
renal glycosuria.
8. Para-aminobenzoic acid salts will not cure lupus erythematosus, but merit
further study in this disease of unknown etiology.
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DISCUSSION
DR. CHARLES R. REIN: Following the report of Zarafonetis, Curtis and Grekin (Uni-
versity Hospital Bulletin, University of Michigan, 13: 122 (Dec.) 1947) on the value of
sodium para-aminobenzoate in the management of certain forms of lupus erythematosus,
Dr. H. H. Sawicky and I undertook the study described below at the New York Skin and
Cancer Unit of the New York Post-Graduate Medical School and Hospital.
Sodium para-aminobenzoate (specially prepared for this study and kindly supplied by
Bristol Laboratories, Syracuse, N. Y., Dr. D. K. Mitchen, Medical Director) in 0.5 gram
tablets and administered in doses of 5 tablets (2.3 gm.) every two hours from 8:00 a.m. to
12:00 midnight for a total daily dosage of 45 tablets (22.5 gm.). The present report deals
with a series of thirteen unselected cases of lupus erythematosus treated for periods ranging
from 1 to 5 weeks. No additional form of therapy was used during the period of study.
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Of the thirteen subjects, varying in age between 24 and 58, seven were white females, two
were colored females and four were white males. Four had the disease for 2—4 years, and
nine for periods of time between 4 and 25 years. Ten of the cases were classified as chronic
discoid and three as chronic disseminated discoid. The latter three cases presented dis-
coid lesions on the face, chest and back but showed none of the systemic manifestations of
acute or sub-acute dissemination of the disease. (All of the subjects had previously been
treated with parenteral bismuth and/or gold with equivocal results.) Three cases were
considered hypersensitive to ultraviolet light on skin testing; ten reacted within normal
limits. The response to treatment was evaluated as poor in aU cases; there being no appre-
ciable improvement in the cutaneous manifestations. The toxic reactions were as follows:
(1) Five patients presented a significant reduction in the white blood cells (3200—3000
W.B.C.) with a beginning depression of the granulocytes during the second and third weeks
of treatment. One of these had repeated attacks of epistaxis. In all instances, the blood
pictures returned to normal within 2—4 weeks following the cessation of therapy.
(2) One male patient experienced a widespread dissemination of lesions on the eighty day
of treatment. Complete blood count, sedimentation rate and urine examinations revealed
nothing of significance. The disseminated lesions cleared within two weeks following ces-
sation of therapy.
(3) One female patient experienced a generalized pruritic erythema on the tenth day of
treatment. This subsided within 48 hours after cessation of therapy. One tablet (0.5
gin.) of the drug, when administered one week later, caused a similar reaction.
(4) One female patient, during the third week of therapy, found it difficult to carry on
with her daily chores because of excessive tiredness and weakness. The patient refused
further treatment or testing with the drug. Repeated urine examinations failed to reveal
any evidence of renal irritation or a lowered sugar threshhold.
In summary, thbteen unselected cases of chronic discoid lupus erythematosus were
treated with oral administrations of sodium para-aminobenzoate. Results were rated poor
in all subjects, there being no appreciable improvement in the cutaneous manifestations.
In eight cases, it was considered advisable to discontinue the drug during the second or
third week of therapy because of one of the side reactions described above.
We therefore concluded that sodium para-aminobenzoate administered by mouth was
found to be of no value in the treatment of thirteen cases of chronic discoid lupus erythem-
atosus. The drug was relatively toxic in the dosage employed in this study.
DR. MAURICE OPPENHEIM: I agree with Dr. Robert H. Grekin, that para-aminobenzoate
has no value in the treatment of lupus erythematosus acutus disseminatus. I treated,
recently, a patient, cadet of West Point, the son of a physician who is a friend of mine,
with the sodium salt of para-aminobenzoate. The treatment was started at West Point
and the Walter Reed Hospital and was continued here. Despite the treatment which was
continued for six weeks, there was no influence on the disease. I called Dr. Arthur Curtis
of the University of Michigan, and he told me to use the drug in an acid solution. The
only effect that the drug had was loss of appetite, vomiting and pains in the abdomen. The
boy died two days ago with a generalized hemorrhagic exanthema besides impetigenous
and ecthymatous lesions of the lower extremities caused by streptococcus hemolyticus.
DR. JEROME M. GREENHOUSE: I was particularly interested in this study, and when the
report appeared I happened to have six cases of lupus erythematosus under treatment in
private practice. Three were cases of disseminated lupus erythematosus and I placed all
three on the schedule which Dr. Curtis used. Two died and one recovered. Another ease
had acute disseminated lupus erythematosus with complicating pulmonary tuberculosis.
This patient was also placed on NaPABA and after approximately two and one-half weeks
jaundice and hepatitis developed. The patient was taken off the NaPABA and placed on
streptomycin. The jaundice cleared up and the temperature returned to normal. I now
have three cases of chronic lupus erythematosus which are on NaPABA. There have been
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no toxic reactions in these three cases. Two are practically well and the other one is hold-
ing its own.
DR. DONALD M. PILLSBURY: I have had a rather limited experience in the treatment of
acute disseminate lupus erythematosus with PABA, and this has been disappointing.
There are two points on which I would like to ask questions. It is well known that in the
treatment of Rocky Mountain spotted fever and scrub typhus there may be tremendous
individual variation in the serum levels and excretion of PABA. I am wondering whether
the authors have had any opportunity to do blood levels or excretion studies? The other
question concerns the finding of glycosuria, which is remarkable and unexpected. I believe
16 out of 18 patients showed this. Was this proven to be glucose as such?
Da. ROBERT H. GREKIN: In answer to Doctor Pillsbury, all types of studies were done
on sugar and it proved to be glucose. Blood levels were done on almost all the patients and
it was attempted to keep the blood level of PABA between 15—20 mgms. No excretion
studies were done. I am gratified that Dr. Greenhouse got some encouraging results in
his cases of lupus erythematosus. I would like to add that most of the cases we have treated
had been previously treated on numerous forms of therapy: bismuth, arsenic, gold, local,
etc., and all failed to respond, or if they did respond at any time, they became intolerant
to the substance so that it had to be discontinued. NaPAB was given as a last resort,
since no other treatment could be used. The only explanation for the results cited by Dr.
Rein and his co-workers is that they may have used some different substance. We will
try their product and see what results we get at Ann Arbor.
